MedTrace Logo

Artificial Intelligence in Breast Cancer Screening in Region Östergötland Linkoping

NCT05048095 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15500

Last updated 2022-04-20

No results posted yet for this study

Summary

The purpose of this observational study is to assess whether the use of AI (Transpara®) can lead to an improved quality of a double reading mammography screening program. This is investigated by performing AI as a third reader and as a decision support during the consensus meeting, compared with conventional mammography screening (double reading and consensus without AI).

Conditions

Interventions

OTHER

AI cancer detection system

The use of AI as a third reader and as a decision support system during consensus meeting

Sponsors & Collaborators

  • Ostergotland County Council, Sweden

    lead OTHER

Principal Investigators

  • Håkan Gustafsson, PhD · Linköping University - University Hospital

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-15
Primary Completion
2022-02-15
Completion
2022-02-15

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05048095 on ClinicalTrials.gov